(CDXC) Chromadex - Ratings and Ratios

ChromaDex Corporation (NASDAQ:CDXC) is a bioscience company specializing in healthy aging innovations. The company operates through three distinct business segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. ChromaDex is renowned for its research into nicotinamide adenine dinucleotide (NAD+), a coenzyme vital for cellular energy metabolism and DNA repair. The company markets finished dietary supplements containing its proprietary ingredients, such as TRU NIAGEN, directly to consumers and distributors. TRU NIAGEN is a consumer-facing brand that leverages NIAGEN, a patented nicotinamide riboside (NR) ingredient, which serves as an NAD+ precursor. Additionally, ChromaDex offers Immulina, a spirulina extract rich in Braun-type lipoproteins, which supports immune function. Beyond consumer products, the company develops and commercializes proprietary ingredient technologies, supplying raw materials to manufacturers of consumer goods. ChromaDex also provides phytochemical reference standards and research services, catering to the pharmaceutical, nutraceutical, and cosmetic industries. Its distribution network includes a proprietary e-commerce platform (TRUNIAGEN.com), Amazon, ShopHQ, specialty retailers, and direct sales to healthcare practitioners. Founded in 1999 and headquartered in Los Angeles, California, ChromaDex has established itself as a leader in the bioscience sector, focusing on advancing the science of aging and metabolic health.

From a technical perspective, CDXC is currently trading at $5.44 with a 20-day moving average of $5.62 and a 50-day moving average of $5.64. The stock is below its 200-day moving average of $4.34, indicating potential long-term downside. Resistance levels at $6.9 and $7.6 could pose challenges for upward momentum. The average trading volume over the past 20 days is 366,081 shares, with an average true range (ATR) of $0.26, suggesting moderate volatility.

Fundamentally, ChromaDex has a market capitalization of $414.00M, with a trailing P/E ratio of 271.00 and a forward P/E of 43.86. The price-to-book ratio stands at 12.66, while the price-to-sales ratio is 4.52. The return on equity (RoE) is 4.32%, reflecting moderate profitability relative to shareholder equity. These metrics suggest a company with high growth expectations but also elevated valuations.